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Fludarabine as a cost-effective 
adjuvant to enhance engraftment 
of human normal and malignant 
hematopoiesis in immunodeficient 
mice
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There is still an unmet need for xenotransplantation models that efficiently recapitulate normal and 
malignant human hematopoiesis. Indeed, there are a number of strategies to generate humanized mice 
and specific protocols, including techniques to optimize the cytokine environment of recipient mice and 
drug alternatives or complementary to the standard conditioning regimens, that can be significantly 
modulated. Unfortunately, the high costs related to the use of sophisticated mouse models may limit 
the application of these models to studies that require an extensive experimental design. Here, using an 
affordable and convenient method, we demonstrate that the administration of fludarabine (FludaraTM) 
promotes the extensive and rapid engraftment of human normal hematopoiesis in immunodeficient 
mice. Quantification of human CD45+ cells in bone marrow revealed approximately a 102-fold increase 
in mice conditioned with irradiation plus fludarabine. Engrafted cells in the bone marrow included 
hematopoietic stem cells, as well as myeloid and lymphoid cells. Moreover, this model proved to be 
sufficient for robust reconstitution of malignant myeloid hematopoiesis, permitting primary acute 
myeloid leukemia cells to engraft as early as 8 weeks after the transplant. Overall, these results present 
a novel and affordable model for engraftment of human normal and malignant hematopoiesis in 
immunodeficient mice.
In the 2000s, various immunodeficient models were developed by combining the IL-2rgnull gene with conven-
tional Prkdcscid and Rag1/2null mutations. These strains showed high levels of engraftment and differentiation of 
human hematopoietic progenitor cells, leading to remarkable advances in the development of human disease 
models1. Nevertheless, humanized mouse models are still under development, and various protocols have been 
established to improve human cell engraftment, in terms of rate, endurance, and function. Techniques to achieve 
higher levels of human cell engraftment at earlier time points include the identification of: 1) optimal sources of 
stem cells, 2) route of donor cell administration, 3) methods to modulate the cytokine environment of recipient 
mice, and 4) drug alternatives or complementary to the standard conditioning regimens. Furthermore, the identi-
fication of the factors responsible for a better engraftment of malignant human hematopoiesis, in particular, acute 
myeloid leukemia (AML) samples derived from patients, would be highly desirable to improve the recapitulation 
of the disease2.
In recent years, fludarabine has been used as a single agent or in combination with other drugs in the condi-
tioning regimen before allogeneic stem cell transplantation3–7. This nucleoside analogue is also well known for its 
immunosuppressive properties, independently of its incorporation into DNA, which results in leuko- and lym-
phopenia in patients8. Notably, it has been shown that the fludarabine-induced immunosuppression is associated 
with the inhibition of the cytokine-induced activation of STAT1 and STAT1-dependent gene transcription in 
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Figure 1. Fludarabine enables efficient human cell reconstitution. (A) Representation of experimental outline: 
irradiation (250 cGy) and 200 mg/kg fludarabine treatment of SCID/beige mice followed by transplantation 
of hCD34+ cells. Where not otherwise specified, mice were euthanized 6 weeks (day 42) after treatment to 
analyse chimerism in hematopoietic organs. Mice receiving only irradiation constitute the control group. (B) 
Percentages of engrafted mice that survived (defined by more than 0.1% hCD45 cells within BM) in the two 
experimental groups at the fixed end-point. 10 independent experiments (2–4 mice/experiment); (C) Kaplan-
Meier curve of overall survival of mice treated with irradiation + fludarabine (gray line) versus irradiation 
(black line). P value by log-rank Mantel-Cox test. 10 independent experiments (2–4 mice/experiment); (D) 
SCID/beige mice receiving irr+ fluda or irr were weighed over 6 weeks following the conditioning procedure 
(on left) and their blood was collected at sacrifice for testing white blood cells (WBC), platelets (PLT) and 
hemoglobin (Hb) (on right). Percent change in body weight is represented as mean and standard deviation. 
Blood parameters are represented by boxplot graph, showing the exact data values by black dots. P values by 
Wilcoxon test. 10 independent experiments (2–4 mice/experiment); (E) Human engraftment in irr+ fluda 
treated or irr SCID/beige mice. On the top, representative dot plots showing hCD45+ cells in PB, BM and 
spleen 6 weeks after transplantation. On the bottom, proportion and absolute numbers of hCD45+ cells in the 
same groups. 10 independent experiments (2–4 mice/experiment); (F) Relative proportion of myeloid (CD33+) 
and B lymphoid (CD19+) cells within the human graft in irr+ fluda mice at 6 weeks. 2 independent experiments 
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normal resting or activated lymphocytes9. Fludarabine could have also a role within the bone/marrow microen-
vironment since it has been demonstrated that this drug significantly increases bone formation in a heterotopic 
ossification model and promotes osteoclastogenesis10,11.
Despite numerous clinical studies in human hematopoietic stem cell transplantation, there are inadequate 
studies on the cytotoxic activity of fludarabine in a limited number of animal models. Within the context of 
bone marrow (BM) transplantation, fludarabine has been mainly administered in graft-versus-host disease mouse 
models12–14.
In our study, we have investigated whether the addition of fludarabine to irradiation in the conditioning regi-
men of a xenotransplantation mouse model would make recipients more permissive for the engraftment of nor-
mal and malignant human cells.
Results
Fludarabine enables efficient human cell reconstitution. We decided to adopt the SCID/beige mouse 
model based on the fact that if mice are conditioned with a sublethal dose of irradiation, they exhibit low levels 
of human engraftment15. Fludarabine was injected intraperitoneally in mice that were previously irradiated with 
250 cGy. Two days later, human cord blood (CB)-derived CD34+ cells (hCD34+) were injected intravenously 
(Fig. 1A). Mice irradiated with the same dose and transplanted with hCD34+ cells derived from the same CB 
donor but not receiving fludarabine were used as controls.
We determined the toxicities of these two conditioning regimens by measuring survival, body weight and the 
blood counts. The addition of fludarabine did not significantly worsen the survival rate of the treated mice over 6 
weeks compared to control mice (p = 0.74), but caused a substantial reduction in body weight only at early points 
after conditioning. Otherwise, all blood parameters were comparable (Fig. 1C,D).
The addition of fludarabine to irradiation resulted in a larger extent of human engraftment, when compared to 
the control group receiving only irradiation (Fig. 1B). Quantification of human CD45+ (hCD45+) cells in BM at 
6 weeks after the transplant revealed a significant difference between the two groups both in proportion (median 
58.3% in Irr+ Fluda, range from 10.49 to 90.34%; 0.64% in Irr, range from 0.11 to 4.60%; p = 0.0011) and abso-
lute numbers (median 7.4 × 106 in Irr+ Fluda, range from 2.25 to 13.6 × 106; 0.06 × 106 in Irr, range from 0.01 to 
0.30 × 106; p = 0.0015) (Fig. 1E). A similar difference in the levels of human cell engraftment was also observed in 
spleen and peripheral blood (PB), in which in the presence of fludarabine the increase was 17- and 96-fold higher, 
respectively. BM analysis showed human engraftment to be multilineage, consisting not only of myeloid (CD33+) 
but also B lymphoid (CD19+) cells (Fig. 1F). Fludarabine by itself was not sufficient to increase human engraft-
ment, resulting in engraftment levels significantly lower than those obtained with the combination of fludarabine 
and irradiation (data not shown).
In order to understand whether the synergistic effect of fludarabine was the result of remodelling the hemato-
poietic niche10,11 or an immunosuppressive effect, we tested the approach in a syngeneic murine transplantation 
model, using donor-recipient pair congenic for a CD45 polymorphism (Fig. 1G). The addition of fludarabine did 
not change the engraftment levels obtained with irradiation only both at 4 and 6 weeks post-transplantation, also 
after administrating very few donor cells, thus suggesting that the fludarabine effect should be related to its immu-
nosuppressive effect rather than an activity on the BM microenvironment. Moreover, we proved that the capacity 
of murine splenocytes to proliferate after in vitro stimulation with Concanavalin A was markedly inhibited by 
fludarabine (Supplementary Fig. S1).
Notably, the administration of fludarabine promoted an early engraftment of human hematopoiesis in trans-
planted mice, in which it was possible to observe a detectable percentage of human cells in BM since the second 
week after transplant (median 0.23% hCD45+ cells, range from 0.11 to 1.78%) (Fig. 1H). The long-term reconsti-
tution induced by fludarabine was durable, since we could still detect the presence of hematopoietic precursors 
CD34+ 12 weeks after transplantation (Fig. 1I).
Fludarabine promotes AML engraftment. We applied the conditioning regimen to evaluate the effect 
on the engraftment of acute myeloid leukemia (AML) that is notoriously difficult to engraft in SCID models. Also 
in this case, the addition of fludarabine to irradiation could favour the engraftment of the AML cell line KG-1. 
The presence of high percentages of AML cells within BM (median 78.91%, range from 66.24 to 97.59%) was 
accompanied by signs of distress, including weakness, weight loss, hunched back, loss of ambulation, laboured 
breathing and paralysis, and mice were humanely killed within 3 weeks when transplanted with 2 × 106 KG-1/
mouse (Fig. 2A,B). Using the same conditioning strategy, it was possible to transplant lower numbers of cells 
(5 × 105 or 2 × 105/mouse) obtaining dose-dependent sustained engraftment levels, with a longer overall sur-
vival (from 21 to 29 days) (Fig. 2C). Finally, we evaluated if this preconditioning strategy could sustain the 
engraftment of primary AML blasts derived from 8 patients with various genetic backgrounds, including NPM-1 
mutated, Flt3 mutated, NPM-1/Flt3 mutated and wild type (Fig. 3A). Strikingly, primary AML samples injected 
in fludarabine-preconditioned mice produced a detectable engraftment in 50% of transplanted AML cases, within 
the first 8 weeks after transplantation. Leukemic cells infiltrated BM (range from 1.5 to 71.5% hCD45+hCD33+, 
(2–3 mice/experiment); (G) Frequency of donor hematopoiesis in PB 4 and 6 weeks after transplantation of 
mice irradiated (200, 400 or 850 cGy), treated or not with fludarabine and injected with 0.5 or 0.05 × 106 BM 
cells of congenic mice. 2 independent experiments (3 mice/group in each experiment); (H) Levels of human 
chimerism analysed in PB and BM of recipient mice at 2, 4 and 6 weeks after conditioning with irr+ fluda. 2 
independent experiments (2–3 mice/experiment); (I) Long term human engraftment (at 12 weeks) in irr+ fluda 
treated mice and presence of hCD34+ precursors.
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evaluated at 8 weeks) and hematopoietic organs (spleen, range from 0.8 to 7.6% hCD45+hCD33+ and PB, range 
from 1.4 to 19.6% hCD45+hCD33+, evaluated at 14 weeks), the primary sites of clinical AML (Fig. 3B,C). Flow 
cytometry data correlated with immunohistochemistry analysis (Fig. 3C).
Discussion
In recent years, fludarabine has been adopted as a single agent or in combination with other drugs for the treat-
ment of various hemato-oncologic malignancies and has been shown to be particularly effective in indolent 
lymphoproliferative disorders, predominantly chronic lymphocytic leukemia (CLL) and follicular lymphoma. 
Furthermore, combination regimens containing fludarabine have also been administered in the treatment of 
aggressive lymphomas and acute leukemias. The inclusion of fludarabine in the conditioning regimen of allo-
geneic stem cell transplantation was initially proposed for its remarkable immunosuppressive activities8. Most 
recently, due to its synergistic cytotoxic activity against both myeloid and lymphoid malignancies when used in 
combination with alkylating agents or radiotherapy, it has now become a standard of treatment in allogeneic stem 
cell transplantation4–7. Indeed, the use of fludarabine-containing regimens has modified the incidence and the 
degree of graft-versus-host disease (GVHD) in these patients.
In experimental BM transplantation, fludarabine has been mainly administered in graft-versus-host dis-
ease12–14. To date, no study has addressed the ability of fludarabine to favour the engraftment of normal and 
malignant hematopoiesis in a mouse model. Our data convincingly show that the administration of fludarabine 
in irradiated mice renders SCID/beige mice excellent recipients not only for normal human hematopoietic cells, 
but also for the leukemic counterparts.
Figure 2. Fludarabine promotes AML cell line engraftment. (A) SCID/beige mice were intravenously injected 
with 2 × 106 cells from the established human myeloid cell line KG-1 on day 2 post conditioning (irr+ fluda or 
irr). Mice were euthanized for the engraftment assessment in PB, BM and spleen when they developed signs 
of overt leukemia. Upper panels, exemplary data from one representative experiment; lower panels, presence 
(as percentages and numbers) of hCD33+ cells in PB, BM and spleen of transplanted mice. 2 independent 
experiments (2–3 mice/group in each experiment); (B) Weight loss in SCID/beige mice conditioned with irr+ 
fluda (gray line) or irr (black line) and transplanted with KG-1 cells. 2 independent experiments (2–3 mice/
group in each experiment); (C) SCID/beige mice were treated with irr+ fluda and injected with two different 
doses (5 × 105 or 2 × 105 cells/mouse) of KG-1 cells. At euthanasia, the engraftment level in PB, BM and spleen 
was assessed by flow cytometry as a proportion (on left) or as absolute numbers (on right). 3 independent 
experiments (3–6 mice/group in each experiment).
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Figure 3. Fludarabine permits engraftment of primary AML blasts. (A) Clinical characteristics of AML patients 
(age, source and percentage of blasts, Fab classification, NMP-1 and Flt3 mutational status) and engraftment 
details (transplanted cell dosage and % human engraftment detected in BM at final analysis) following 
transplantation in SCID/beige mice conditioned with irr+ fluda. NA, not analysed. 8 independent experiments; 
(B) Representative dot plots showing hCD33+ blasts in PB, BM and spleen of SCID/beige mice previously 
treated with irr+ fluda (patient #6). (C) Representative paraffin sections from the same mouse (patient #6) 
stained with Hematoxylin and Eosin (top panel) to show the human blasts infiltrating the BM. The infiltrating 
blasts display a myeloid phenotype as proved by their immunoreactivity with anti-hCD33 and MPO antisera. 
Bars: 100 µm in the top panel and 20 µm in the bottom panels.
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The in vivo kinetics of fludarabine suggest to wait at least 48 hours before infusing hematopoietic stem cells to 
enable the complete clearance of the drug and potential toxic effects on the graft3.
Therefore, in our hands fludarabine can be exploited to obtain a fast and durable human engraft-
ment in low-care immunodeficient strains. The mechanism of this phenomenon could be ascribed to the 
fludarabine-induced immunosuppression associated with the cytotoxic potential against lymphocytes due to the 
inhibition of STAT1 signaling9. The fact that fludarabine does not enhance the engraftment level in a congenic 
model seems to support this hypothesis. The inhibition of mitogen-induced murine splenocyte proliferation by 
fludarabine supports the hypothesis that it may control the host lymphocyte leakage that interferes with the 
human graft16. SCID/beige mice are congenic mice that possess both genetic autosomal recessive mutations SCID 
(Prkdcscid) and beige (Lystbg). The beige mutation results in defective NK cells. The SCID mutation results in defi-
ciency in V(D)J recombination, producing severe lymphopenia but not absolute absence of T and B cells. Indeed, 
through the incomplete penetrance (“leakiness”) of the scid mutation, occasional productive VDJ rearrangement 
can occur and give rise to clonal expansion of limited T and B cell clones16. A similar leaky phenotype is also 
described in SCID/beige mice17. Leaky SCID lymphocytes can respond to mitogens, are capable of producing 
cytokines and serum Ig, and may develop reaction to allogeneic tissue18. For instance, it is possible that the immu-
nosuppressant drug fludarabine could affect the residual T and B lymphocytes in SCID/beige mice, that may 
represent a potential interference with graft acceptance.
In summary, we demonstrate that the administration of fludarabine promotes in SCID/beige mice an extensive 
and durable engraftment of normal human hematopoiesis that exceeds the levels currently achievable in other 
models. The engraftment comprised hematopoietic stem cells as well as myeloid and lymphoid cells and could be 
reproduced using cells sourced from myeloid malignancy. The disease phenotype observed in leukemia-engrafted 
mice recapitulated the features of the human counterpart. We conclude that fludarabine treatment may provide 
a tool to maximise normal and malignant xenotransplantation in otherwise inefficient but relatively inexpensive 
immunocompromised recipients such as SCID/beige mice. The approach could be applied to other existing mod-
els of diseases (e.g., SCID models of rare genetic disorders) that remain in need of sufficiently informative levels of 
human engraftment. Overall, our results provide novel and affordable information for the engraftment of human 
normal and malignant hematopoiesis in immunodeficient mice.
Methods
Study approval. All animal experiments were performed under license approved by the Italian Ministry of 
Health and in accordance with Italian Cancer Research guidelines. The use of umbilical cord blood (UCB) and 
AML samples was approved by the Ethics Committee of San Gerando Hospital-Monza and carried out in accord-
ance with the Declaration of Helsinki. All samples were only processed from patients who had consented the use 
of biological material for ethically approved research.
Cell lines and primary AML samples. Human AML cell line KG-1 (obtained from the ATCC) was main-
tained in culture, splitting every 2–3 days, in Advanced RPMI medium (Invitrogen) supplemented with 10% 
heat-inactivated fetal bovine serum (Biosera), 2 mM L-glutamine, 50 IU/ml of penicillin and 50 μg/ml of strep-
tomycin (Lonza).
For primary acute myeloid leukemia samples, PB or BM samples from adult or pediatric patients were col-
lected at diagnosis. Samples were enriched for mononuclear cells by using a Ficoll-Paque gradient, and subse-
quently frozen in 10% dimethyl sulfoxide solution (Sigma-Aldrich). Details of patients’ samples are provided in 
Fig. 3.
Xenotransplantation procedures. Animals were used in accordance with a protocol approved by the 
Italian Ministry of Health. Adult (10–12 weeks old) SCID/beige (CB17.Cg-PrkdcscidLystbg-J/Crl) mice purchased 
from Charles River Laboratories (Calco, Italy) were sublethally irradiated (250 cGy) and treated with 200 mg/kg 
Fludarabine (Teva) by intraperitoneal administration, 48 h before intravenous injection of human cells.
For normal reconstitution, CD34+ progenitors from human CB were obtained by Ficoll-Paque Plus (GE 
Healthcare Europe) separation of the mononuclear fraction followed by immunomagnetic selection using the 
CD34 MicroBeads kit (Miltenyi Biotec). 10 independent hCD34+ batches were used for transplantation experi-
ments, with an average purity of 81% (range: 70–95.2%).
For leukemic reconstitution, cultured AML cell line KG-1 or freshly thawed PB/BM samples from patients 
with AML were used for transplants.
Daily monitoring of mice for symptoms of disease (ruffled coat, hunched back, weakness and reduced motil-
ity) determined the time of euthanasia for injected animals with signs of distress.
Engraftment evaluation. Human engraftment (defined as more than 0.1% human cells in murine BM) 
was assessed in PB, BM and spleen at defined time points (in the case of normal hematopoietic cells transplant) 
or at signs of distress (in the case of AML cell line KG-1 transplant). Engraftment of human cells (in the case of 
primary patient-derived AML cells) was evaluated in BM at 8 weeks after transplantation (analyzing femoral BM 
aspirates) and in spleen and PB at the time of euthanasia (14 weeks). Kaplan-Meier survival analysis and body 
weight assessment were performed on all animals.
For engraftment evaluation, 50 µL of PB were collected in heparin by tail bleeding, analyzed with hematology 
counter (Coulter AcT Diff, Beckman Coulter), and lysed with ACK (Ammonium-Chloride-Potassium) lysing 
buffer (Stem Cell Technologies). BM (mixed from tibiae and femora) was collected by flushing long bones, while 
splenocytes were collected by smashing spleen on a 70 µm cell strainer (Greiner Bio-One). Single cells suspen-
sions were counted in Bürker chamber with Turk solution and processed for analysis by flow cytometry.
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Flow cytometry and histopathology. For flow cytometry analyses, fluorescent antibodies against murine 
CD45.2 (clone 104, eBiosciences) and against human CD45 (clone HI30), CD33 (clone P67.6), CD34 (clone 
8G12), CD19 (clone SJ25C1) (BD Biosciences), and CD45 (clone HI30, Invitrogen) were used. The analyses were 
performed on a FACS CantoII (BD Biosciences).
Humeri of fludarabine-treated SCID/beige mice transplanted with primary human AML blasts were fixed in 
4% formaldehyde in phosphate buffer, decalcified in 10% EDTA (Sigma-Aldrich) and routinely processed for par-
affin embedding. Serial 5 µm-thick sections were stained with Hematoxylin-Eosin and stained with anti-human 
CD33 (# NCL-L-CD33, clone PWS44, 1:100; Novocastra™) and Myeloperoxidase (#NCL-MYELO, clone 59A5, 
1:100, Novocastra™) antisera.
Murine BM transplantation. For murine BM transplantation experiments, 12-week-old C57BL/6-CD45.2 
mice were conditioned by irradiation alone or followed by injection of fludarabine and BM cells from congenic 
C57BL/6-CD45.1 mice were transplanted by a single intravenous injection within 48 hours from conditioning. 
In one experimental setting mice received a sublethal irradiation (200 or 400 cGy) with the infusion of 0.5 × 106 
donor cells/mouse and in the other one an irradiation of 850 cGy with 0.05 × 106 donor cells/mouse.
For engraftment evaluation, 50 µL of PB were collected 4 and 6 weeks after transplant in heparin by tail bleed-
ing, lysed with ACK buffer and stained with antibodies against murine CD45.1 (clone A20, eBiosciences) and 
CD45.2 (clone 104, eBiosciences).
Immunosuppressive assay. 5 × 105 C57BL/6 murine splenocytes were labelled with PE-Cell Tracker 
(ThermoFisher Scientific), plated in the presence or in the absence of fludarabine (2.5 mcg/ml) for 24 hours, and 
then stimulated with ConA (3 mcg/ml). Controls consisted of splenocytes plated without ConA. Proliferation was 
assessed by flow cytometry after 72 hours. Cell counts were determined by adding CountBright absolute counting 
beads (Molecular Probe) to the flow cytometric samples.
Statistical analysis. Unless otherwise stated, data are represented as median and range. Nonparametric 
Wilcoxon test for equality of the medians was used to calculate P-values. Significance is represented as follows: 
*P < 0.05, **P < 0.01, ***P < 0.001.
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